- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05377723
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Adult (>18 years) women who have undergone microsurgical breast reconstruction with free abdominal flap(s) approximately 1 week (5-10 days) prior to study participation will be approached by the clinical research team during their first postoperative clinic visit; the protocol asks for the device to be applied at this point. Investigators will only invite those subjects to participate whose incisions, at the 1 week postoperative visit, appear to be uniformly aesthetically similar across the length of the incision. Informed consent for randomization and study participation will be obtained.
After eligible patients have provided informed consent, the side of the abdomen to be treated with the Neodyne Device will be randomly selected by opening a sealed randomization envelope. The selected side will be treated with the Neodyne Device through the full study. The Neodyne Device will be applied to a portion of the abdominal incision by the health care provider at 1 week (4-8 days) after the procedure. The other portion of the abdominal incision will serve as the control and will be treated per the investigator's standard of care. Subjects will return to the Investigator's office for a total of 8 weeks for application and removal of the Neodyne Dressing.
At the 8th week visit subjects and investigators will complete an evaluation of the incision/scar. Subjects will return to the Investigator's office at 12 weeks from the date of the procedure for another evaluation of the incision/scar. The primary study endpoint will be evaluated at 6 months from the date of the procedure. Subjects will also be offered the opportunity to provide additional photographic evaluations at 12 months after surgery in conjunction with a standard clinic visit.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shannon Meyer
- Phone Number: 650-721-1807
- Email: smeyer27@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University Medical Center
-
Contact:
- Arash Momeni, MD
- Phone Number: 650-723-6189
- Email: smeyer27@stanford.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female Subjects who have undergone unilateral/bilateral microsurgical breast reconstruction with free abdominal flaps within approximately 1 week (4-8 days) prior to study participation.
- Appearance of subject's incision is aesthetically similar across length of incision
- Age >18
- Subject has the ability to read and comprehend as required by the protocol and the informed consent.
- Subject must be able to provide written informed consent prior to participation in the study.
Exclusion Criteria:
- Subjects with a history of collagen vascular disease, cutis laxica, connective tissue disease, psoriasis, or lupus.
- Subjects diagnosed with scleroderma.
- Subjects with known adverse reactions to steri-strip tapes, medical tapes, or adhesives.
- Subjects with oozing, dehiscence, non-closed/healed incisions at time of first application.
- Subjects with inability to maintain adequate care of incision.
- Subjects with a weight loss of > 100 lbs within 6 months from date of surgery.
- Subjects who currently smoke.
- Subjects taking steroid therapy (systemic or inhaled) within 2 months from date of study enrollment.
- Subject does not qualify for the study in the opinion of the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neodyne Device
After eligible patients have provided informed consent, the side of the abdomen to be treated with the Neodyne Device will be randomly selected by opening a sealed randomization envelope.
The selected side will be treated with the Neodyne Device through the full study.
The Neodyne Device will be applied to a portion of the abdominal incision by the health care provider at 1 week (4-8 days) after the procedure.
The other portion of the abdominal incision (Arm Title: Control) will serve as the control and will be treated per the investigator's standard of care.
Subjects will return to the Investigator's office for a total of 8 weeks for application and removal of the Neodyne Dressing.
|
See Arm Description: Neodyne Device
|
Other: Control
See above
|
See Arm Description: Neodyne Device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scar Assessment
Time Frame: 6 months
|
The primary endpoint is the difference between the assessments of the scar appearance for the treated as compared to the control incision sites.
Incisions will be evaluated by an objective independent expert panel at six months post surgery.
The panel will review close-up photographic records, taken at the 6 month study endpoint, of the control incision site and the treated incision site.
The subject will complete the Scar Q questionnaire and both the investigator and the subject will complete the Patient and Observer Scar Assessment Scale (POSAS).
It is expected that the scar from the incision area covered by Neodyne Dressing will be minimized when compared to the scar from the untreated incision area.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Arash Momeni, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 59506
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cicatrix
-
Samsung Medical CenterSeoul National University Hospital; Kyunghee University Medical Center; InovailUnknownHypertrophic CicatrixKorea, Republic of
-
Olix Pharmaceuticals, Inc.CompletedCicatrix, HypertrophicUnited Kingdom
-
HugelCompletedHypertrophic ScarKorea, Republic of
-
SolitonUnited States Naval Medical Center, San DiegoNot yet recruitingScars, Hypertrophic
-
Seton Healthcare FamilyCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedCicatrix, HypertrophicSpain
-
Nova Scotia Health AuthorityRecruiting
-
Henry Ford Health SystemActive, not recruitingScar | Hypertrophic ScarUnited States
-
Massachusetts General HospitalWithdrawnHypertrophic ScarsUnited States
-
The Hospital for Sick ChildrenCompleted
Clinical Trials on Neodyne Device
-
Neodyne Biosciences, Inc.U.S. Army Medical Research and Development CommandCompleted
-
Neodyne Biosciences, Inc.Completed
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden
-
Cala Health, Inc.Not yet recruiting
-
International Agency for Research on CancerUniversity of North Carolina Global Project Zambia; Liger Medical LlcCompleted
-
Universitair Ziekenhuis BrusselTerminated
-
University of BernDCB Research AG; Insel Gruppe AG, University Hospital BernActive, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseSwitzerland
-
Massachusetts General HospitalCase Western Reserve UniversityRecruitingSurgery--ComplicationsUnited States